Turning around the Jubak Picks portfolio: It takes time (frustrating amounts of time) but by late 2016 the recovery was in place: 2017 total return 13.13% despite 27.2% cash

Turning around the Jubak Picks portfolio: It takes time (frustrating amounts of time) but by late 2016 the recovery was in place: 2017 total return 13.13% despite 27.2% cash

March 19, 2018 | Daily JAM, Mid Term | 4 comments

Turning around a portfolio can take a frustratingly long time. The Jubak’s Picks portfolio has had a performance problem since 2014. But I think I’ve finally put a recovery in place. The total return on the portfolio was 13.1% in 2017. That still badly lagged the 21.7% total return on the Standard & Poor’s 500. But it’s promising–considering that the portfolio finished the year 27.2% in cash. (Which itself was better than the 37% cash at the end of 2016.)

FDA sets next date for Incyte arthritis drug, baricitinib

Bristol-Myers puts up potential $3.6 billion in deal for 35% of a Nektar cancer drug

February 14, 2018 | Daily JAM, NKTR, Stock Alerts | 0 comments

In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate still in trials and that has shown the ability to extend the range of Bristol-Myers Opdivo

FDA sets next date for Incyte arthritis drug, baricitinib

Nektar soars today on J.P. Morgan healthcare conference

January 9, 2018 | Daily JAM, Morning Briefing, NKTR, Stock Alerts | 0 comments

Anybody still think that conferences, especially biotech conferences, don’t move stock prices? Shares of Nektar Therapeutics (NKTR) are up 7.65% today to $61.79 as of noon New York time on the company’s appearance at this week’s J.P. Morgan biotech conference. The slides from the company’s presentation today are in circulation but CEO Howard Robin doesn’t actually present until 2 p.m. New York time today.